Barinthus Bio Q1 net loss $15.5M; VTP-200 misses stat sig; VTP-1000 IND cleared; CMO appointed

Barinthus Biotherapeutics plc.

2024-Q1 EPS reported -$0.40

Net loss was $15.5M ($0.40/share), compared to $18.2M ($0.48) in Q1 2023; revenue nil.
Cash position $130.0M as of Mar 31, 2024; cash runway into Q4 2025.
VTP-200 Phase 1b/2 APOLLO met safety but no stat sig improvement in hrHPV or lesion clearance vs placebo.
VTP-1000 IND cleared for Phase 1 celiac trial; first patient dosing expected Q3 2024.
Appointed Dr. Leon Hooftman as CMO effective June 3, 2024.

item 7.01 item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Barinthus Biotherapeutics plc. reported first quarter of 2024 results: revenue nil.

Period: first quarter of 2024
Revenue: nil
Result: reported results

Exact text from the filing

On May 13, 2024, the Company announced its financial results for the first quarter of 2024

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-24-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.